Abstract:Background: As an immunogenic cancer, crosstalk between cancer cells and immune cells has been gradually recognized in bladder cancer (BC). Several studies have emphasized the clinical significance of the molecular stratification of BC without highlighting the role of the immune microenvironment. Although immunotherapy acted as a prospective treatment, more precise molecular stratification should be established to select those sensitive to immunotherapy. Methods: To select specific immune genes forming subtypes indicating disparate prognoses, we performed bioinformatic analysis using BC transcriptomic profiles from six published datasets, with 408 BC samples in The Cancer Genome Atlas (TCGA) database and 295 individuals in International Cancer Genome Consortium (ICGC) database. Survival analyses were conducted using Kaplan-Meier curves, while Kruskal-Wallis tests were applied to test the differences among groups. Except for unsupervised clustering based on the differential expression of genes, we additionally performed binomial logistic regression, focusing on the mRNA level of a single sample. Results: Unsupervised clustering showed that 4 clusters captured the best segmentation. After validation with survival data and simplification using binomial logistic regression, we found that cluster B and cluster D showed worse survival outcomes (P=0.012). Considering the similar survival outcomes of these two dusters, we recombined and performed another survival analysis, which also showed significant survival differences (P=0.0041). Bonding with clinical data, a greater proportion of risk factors were assigned to the worse prognosis subtype, especially showing higher grades in the subtype (P<0.001). In addition, immune cell infiltration, single nucleotide polymorphism (SNP) and copy number variation (CNV) all showed differences between clusters, indicating changes in the immune microenvironment and mutation burden. Through phenotypical analysis, we found metabolism and proliferation phenotypes associated with the immune clusters and mutually exclusive in BC, of which proliferation contributed to worse outcomes. Using the tumor immune dysfunction and exclusion (TIDE) score, a worse immunotherapy benefit was predicted in dusters B&D, defined as the worse prognosis subtype. Conclusions: With this novel clustering criterion based on immune-related genes, we provide a better understanding of the immune microenvironment, further guiding the use of immunotherapy.

Multi-Omics Analysis Identifies the Heterogeneity and Prognosis in Bladder Cancer

Multi-omics comprehensive analysis reveals the predictive value of N6-methyladenosine- related genes in prognosis and immune escape of bladder cancer

Single-cell Sequencing Data Reveals Aggressive CD68-type Macrophages and Prognostic Models in Bladder Cancer.

Bioinformatics analysis to screen DNA methylation-driven genes for prognosis of patients with bladder cancer

Heterogeneity Analysis of Bladder Cancer Based on DNA Methylation Molecular Profiling.

A Single-Sample Mrna Molecular Classification of Bladder Cancer Predicting Prognosis and Response to Immunotherapy

A Novel DNA Methylation Signature As an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer

DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder Cancer

Exploring prognostic DNA methylation genes in bladder cancer: a comprehensive analysis

Identification of the role of<i> MCM6</i> in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis

An Independent Poor-Prognosis Subtype Synthesized Single-Sample Mrna Molecular Classification in Tumor Microenvironment of Bladder Cancer

Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non–muscle-invasive bladder cancer using multi-layered –omics studies

Discovery of Bladder Cancer-related Genes Using Integrative Heterogeneous Network Modeling of Multi-omics Data

Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks

Identification of Prognostic Biomarkers for Bladder Cancer Based on DNA Methylation Profile

Prognostic Value Of Differentially Methylated Gene Profiles In Bladder Cancer

Identification of endothelial-related molecular subtypes for bladder cancer patients

A Three Protein-Coding Gene Prognostic Model Predicts Overall Survival in Bladder Cancer Patients

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

Identification of potential DNA methylation biomarkers related to diagnosis in patients with bladder cancer through integrated bioinformatic analysis

Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive Vs. Muscle Invasive Bladder Cancer: A Pilot Study